Markets:

Overview

News

Currencies

International

Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

7.980 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

3 Reasons NVAX is Risky and 1 Stock to Buy Instead

Today 0:05 EDT

Over the last six months, Novavax shares have sunk to $8.21, producing a disappointing 7.7% loss - worse than the S&P 500’s 2.1% drop. This might have invest...

Via StockStory

Topics Stocks

1 Russell 2000 Stock with Exciting Potential and 2 We Avoid

April 07, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Government Stocks World Trade

2 Growth Stocks Set to Flourishand 1 We Question

April 01, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

NOVAVAX INC (NASDAQ:NVAX) Screens as a Minervini-Style High-Growth Momentum Candidate ↗

March 07, 2026

Via Chartmill

A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

March 29, 2026

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio...

Via StockStory

Topics Artificial Intelligence

Novavax (NVAX) Stock Trades Down, Here Is Why

March 27, 2026

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) fell 4.1% in the afternoon session after major indices including the S&P 500 and...

Via StockStory

Topics Economy Government Stocks

3 Stocks Under $50 That Concern Us

March 27, 2026

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Via StockStory

Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

March 24, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Haloz...

Via StockStory

Topics Artificial Intelligence

Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers

March 23, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

March 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks

March 19, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD...

Via StockStory

Topics Artificial Intelligence

Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest

March 19, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

3 Profitable Stocks That Concern Us

March 19, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

March 17, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

Via StockStory

Topics Artificial Intelligence

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

March 09, 2026

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...

Via StockStory

Topics Artificial Intelligence

Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

March 08, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (NASDAQ:AMGN) and its p...

Via StockStory

Topics Artificial Intelligence

Why Novavax (NVAX) Shares Are Falling Today

February 27, 2026

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) fell 8.7% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than...

Via StockStory

Topics Artificial Intelligence Economy Supply Chain

The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines

February 27, 2026

As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of...

Via Finterra

Topics Economy

Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? ↗

February 27, 2026

Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.

Via Stocktwits

Topics Earnings

NVAX Q4 Deep Dive: Partnership-Led Strategy and Pipeline Transition Shape Outlook

February 27, 2026

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its non-GAAP profit of...

Via StockStory

Why Is Novavax (NVAX) Stock Soaring Today

February 26, 2026

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported fourth-quarter financial results that significantly beat analyst...

Via StockStory

Topics Artificial Intelligence Economy

Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗

February 26, 2026

The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11.

Via Stocktwits

Topics Artificial Intelligence

Novavax (NASDAQ:NVAX) Surprises With Strong Q4 CY2025

February 26, 2026

Via StockStory

Topics Artificial Intelligence

NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash ↗

February 26, 2026

Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly.

Via Stocktwits

Novavax (NVAX) Q4 Earnings Report Preview: What To Look For

February 25, 2026

Vaccine biotechnology company Novavax (NASDAQ:NVAX) will be announcing earnings results tomorrow before market open. Here’s what you need to know.

Via StockStory

Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗

February 24, 2026

According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.

Via Stocktwits

Topics Artificial Intelligence Earnings

3 Small-Cap Stocks We Steer Clear Of

February 22, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

3 of Wall Street’s Favorite Stocks We Approach with Caution

February 16, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

3 Stocks Under $10 with Warning Signs

February 15, 2026

Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.